Ligand Pharm (LGND) Stock Price, Quote & News

Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also pr...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 550 7500

Website: www.ligand.com

Address:

555 Heritage Drive, Suite 200, Jupiter, United States

Kool_Aid_Mann May. 8 at 7:53 PM

$VRTX $ALNY $REGN Join MNKD as they approach their May 29th pediatric PDUFA!! This is the one that they have been waiting for for 12 years. Lots of delays, but finally here and likely to be the milestone trigger for a big cash deal with big pharma! On top of that, they just got back the green light for Treprostinil DPI in IPF which had them previously trading over $6 until a spat with their partner UTHR. Now, not only is everything copacetic again, but they have also just announced a new molecule colloboration with bigger potential than Trep, Ralinpag DPI! Big royalty model like $LGND But wait, there's more, there is another PDUFA ahead for them for furoscix on July 26th, that will approve a new auto injector that will make this product best in class and reduce COGs by 70% to create massive profits. And lets not forget that nintedabib DPI just finished 1b and is prime for an upfront cash deal! $VCYT Fireworks ahead, fight the Citadel!

0 · Reply

BillionerOfKing May. 7 at 6:18 PM

$LGND Current Stock Price: $211.09 Contracts to trade: $210.0 LGND May 15 2026 Call Entry: $6.00 Exit: $8.20 ROI: 37% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

StocktwitsEarnings May. 7 at 11:10 AM

$LGND Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.67 up 69.68% YoY • Reported revenue of $51.72M up 14.09% YoY • Ligand reaffirms its 2026 full-year financial guidance, expecting adjusted earnings per diluted share of $8.50 to $9.50 and total revenue of $270M to $310M, reflecting partial-year XOMA contribution.

0 · Reply

Doozio May. 4 at 2:30 PM

$XBI $AXSM BODI. That wen da huckleberries get $ETON n $DRUG z get $LGND ary ONTO 🐒🍌🧠⏰♾️

1 · Reply

jewell69 May. 1 at 4:59 PM

$LGND 1st time by 12:58 pm edt 5/1 05/01/2026 Buy LGND LIGAND PHARMACEUTICALS I 40 $232.995 -$9,319.80

0 · Reply

jewell69 May. 1 at 4:50 PM

trying 2 by 40 $LGND 231.80 now b a 231.67 x 234.32 hi 236.22 lo 226.47 SO FAR as of 12:48 pm edt on 5/1 they also raised numbers Rating — Buy Target Price $230.00 $255.00 FY26E EPS (adj.) $8.66 $9.19 FY27E EPS (adj.) $9.53 $11.44 FY26E Rev (net) $264.3 $289.6 FY27E Rev (net) $308.2 $381.9 the numbers on the left are before, the numbers on the right are now. they are paying just + 14% over average price of the new company.

0 · Reply

jewell69 May. 1 at 4:44 PM

$LGND more stifel 4/27 narrative: ... adding highly complementary, synergistic, and diversified assets to its portfolio and pipeline (expected closing 3Q26). XOMA has a portfolio of long-dated royalty revenues—seven commercial (three growth drivers in Vabysmo, Ojemda and Miplyffa), 14 late-stage, and >100 early-stage assets—strengthening LGND’s leadership position in development stage royalty aggregation and offering a layered strategy to LGND’s growth profile. The XOMA acquisition effectively doubles the size of LGND’s royalty portfolio and brings immediate accretion, increasing 2026 guidance by $25MN ($270–310mn) in royalty revenues and Adjusted Core EPS by $0.50/share ($8.50 9.50). Importantly, despite using cash and its credit line (resulting in minimal dilution), LGND is maintaining its capital flexibility, with cash flow increasing to $300MN, fully funding its annual capital deployment goal of $150 - $250 mn per year.

0 · Reply

jewell69 May. 1 at 4:43 PM

5/1/26 not sure what STIFEL's problem is w/ their focus list, but 3/18 they had both $LGND and $JAZZ with a pt of 230 for both of them. at the time of their writing, jazz was at 181.37 but 5/1/26 it is at 202.30 and LGND was at 211 on 3/18, and as of 5/1 it is at 233.48 (so it is above its pt! but they wrote about it on 4/27 and raised pt from 230 to 255 XOMA Solidifies a Unique Position in Biotech Royalty Aggregation and Development-Stage Assets; Raise TP to $255 $XOMA 40.92 on 5/1 but buyout price is ONLY 39.00

0 · Reply

biolover Apr. 30 at 11:53 PM

$LGND $VKTX This is meritless termination of agreement that will go nowhere Could be driven by a third party that is trying to license Vk2809 from $VKTX for cheap ( as recently rumored ) Now the whole BTR agonism is a weak class and doesn’t have long term competitive edge, regardless whether BB are invested in it or not VK CEO was planning to raise in Nov 2024 but dropped data at OW 2 days prior to election in the most bear market. He can’t veer resources from BIC VK2735 competing in future with $LLY king TZP. This is no impact story long term.. it could force a licensing deal with BP and infuse cash to VK

1 · Reply

DG20 Apr. 30 at 11:40 PM

$LGND $VKTX Ligand owns the molecule/composition of matter patents for VK2809. Viking however owns patents for method-of-use / fibrosis / clinical application IP (IE what can be done with VK2809). If you’ve been here long enough you know Brian Lian holds numerous fibrosis patents for VK2809 assigned in 2024… For as much crap as BL gets he has done a lot of work to protect his assets…

0 · Reply

Market Cap	4.21B
Revenue (ttm)	268.09M
Net Income (ttm)	124.45M
EPS (ttm)	N/A
PE Ratio	39.89
Forward PE	42.62
Profit Margin	46.42%
Debt to Equity Ratio	0.00

Volume	249,900
Avg Vol	238,686
Day's Range	N/A - N/A
Shares Out	20.04M
Stochastic %K	48%
Beta	1.20
Analysts	Strong Sell
Price Target	$265.30